Alzchem Group AG Reports Q3 2026 Results and Updates Nitroguanidin Project

Alzchem Group AG said rising material costs, depreciation and planned startup expenses for new nitroguanidin capacity in Germany weighed on third-quarter 2026 earnings, but it maintained its full-year guidance. The Specialty Chemicals segment continued to grow on demand for creatine and defense-related nitroguanidin, while Basics & Intermediates faced weak agricultural and pharmaceutical demand. Higher-than-planned investment costs for a proposed US nitroguanidin plant prompted the company to renegotiate with the US Department of Defense.